array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(29) "Regeneron Pharmaceuticals Inc"
["slug"]=>
string(38) "c469a-us-regeneron-pharmaceuticals-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77"
["description"]=>
string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. "
["address_street"]=>
string(25) "777 Old Saw Mill River Rd"
["address_place"]=>
string(9) "Tarrytown"
["address_region"]=>
string(8) "New York"
["founding_date"]=>
string(10) "1988-02-08"
["website_domain"]=>
string(13) "regeneron.com"
["website_url"]=>
string(25) "https://www.regeneron.com"
["industry_codes"]=>
array(1) {
[0]=>
string(27) "Pharmaceutical Preparations"
}
["employee_count"]=>
int(10368)
["article_count"]=>
int(2437)
}
["articles"]=>
array(9) {
[0]=>
array(7) {
["title_en"]=>
string(48) "Wall Street Comments on Uber, Lyft and Regeneron"
["snippet_en"]=>
string(167) "Nomura downgraded Uber (NYSE:UBER) shares to neutral buy, raising their target price to $62 from $59, DKNews.kz reports. The firm believes the company's shares are now"
["url"]=>
string(85) "https://dknews.kz/ru/biznes/312002-kommentarii-na-uoll-strit-po-uber-lyft-i-regeneron"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/c73af0e3-5210-440f-8b55-8705c2a06d9a"
["source"]=>
string(9) "dknews.kz"
["publication_date"]=>
string(10) "2024-01-01"
["categories"]=>
array(9) {
[0]=>
string(46) "Management of Legal and Regulatory Environment"
[1]=>
string(5) "Legal"
[2]=>
string(21) "Intellectual Property"
[3]=>
string(8) "Verdicts"
[4]=>
string(18) "General Investment"
[5]=>
string(11) "Acquisition"
[6]=>
string(12) "Stock Market"
[7]=>
string(24) "Stock Research & Ratings"
[8]=>
string(21) "Competitive Behaviour"
}
}
[1]=>
array(7) {
["title_en"]=>
string(38) "Market Trends Report 2023: Shohta Ueno"
["snippet_en"]=>
string(80) "Ueno of Regeneron talks about strategy for the unitary patent and UPC litigation"
["url"]=>
string(94) "https://www.managingip.com/article/2clb9fgrsvbx3uwszx2x2/market-trends-report-2023-shohta-ueno"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/1b85bda3-9e73-4d4d-b70f-4b038b46c130"
["source"]=>
string(14) "managingip.com"
["publication_date"]=>
string(10) "2023-12-18"
["categories"]=>
array(6) {
[0]=>
string(5) "Legal"
[1]=>
string(10) "Litigation"
[2]=>
string(21) "Intellectual Property"
[3]=>
string(5) "R & D"
[4]=>
string(15) "Market Movement"
[5]=>
string(21) "Competitive Behaviour"
}
}
[2]=>
array(7) {
["title_en"]=>
string(70) "How Is The Market Feeling About Regeneron Pharmaceuticals? By Benzinga"
["snippet_en"]=>
string(58) "How Is The Market Feeling About Regeneron Pharmaceuticals?"
["url"]=>
string(113) "https://uk.investing.com/news/stock-market-news/how-is-the-market-feeling-about-regeneron-pharmaceuticals-3240453"
["image_url"]=>
NULL
["source"]=>
string(13) "investing.com"
["publication_date"]=>
string(10) "2023-11-16"
["categories"]=>
array(4) {
[0]=>
string(21) "Competitive Behaviour"
[1]=>
string(5) "R & D"
[2]=>
string(15) "Market Movement"
[3]=>
string(10) "New Market"
}
}
[3]=>
array(7) {
["title_en"]=>
string(101) "Regeneron to sell COVID-19 prophylactic antibody at internationally comparable price By Investing.com"
["snippet_en"]=>
string(84) "Regeneron to sell COVID-19 prophylactic antibody at internationally comparable price"
["url"]=>
string(143) "https://ph.investing.com/news/stock-market-news/regeneron-to-sell-covid19-prophylactic-antibody-at-internationally-comparable-price-93CH-983575"
["image_url"]=>
NULL
["source"]=>
string(13) "investing.com"
["publication_date"]=>
string(10) "2023-09-14"
["categories"]=>
array(2) {
[0]=>
string(21) "Competitive Behaviour"
[1]=>
string(8) "Epidemic"
}
}
[4]=>
array(7) {
["title_en"]=>
string(129) "Pharmalittle: White House imposes price limits for Regeneron Covid drug; lawmakers push federal agencies to prevent patent abuses"
["snippet_en"]=>
string(128) "A HHS deal for a Regeneron drug marks the first time the administration has directly used its leverage to challenge list prices."
["url"]=>
string(144) "https://www.statnews.com/pharmalot/2023/09/14/fda-patents-ftc-regeneron-covid19-medicare-alnylam-abbott-insulin-cepheid-danaher-tb-tuberculosis/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/6bf5bb64-e8d8-4a07-8cc8-f0dfb3d89d62"
["source"]=>
string(12) "statnews.com"
["publication_date"]=>
string(10) "2023-09-14"
["categories"]=>
array(2) {
[0]=>
string(21) "Competitive Behaviour"
[1]=>
string(8) "Epidemic"
}
}
[5]=>
array(7) {
["title_en"]=>
string(108) "Signal- HHS/Regeneron Covid-19 deal includes list price clause for affordability - Pharmaceutical Technology"
["snippet_en"]=>
string(99) "Regeneron is developing an antibody for Covid-19 prevention with the help of US government funding."
["url"]=>
string(127) "https://www.pharmaceutical-technology.com/news/signal-hhs-regeneron-covid-19-deal-includes-list-price-clause-for-affordability/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/5979cd7a-eb11-4458-be76-63f80c4a3721"
["source"]=>
string(29) "pharmaceutical-technology.com"
["publication_date"]=>
string(10) "2023-09-12"
["categories"]=>
array(2) {
[0]=>
string(21) "Competitive Behaviour"
[1]=>
string(8) "Epidemic"
}
}
[6]=>
array(7) {
["title_en"]=>
string(29) "REGENERON PHARMACEUTICALS INC"
["snippet_en"]=>
string(125) "Learn about the historical price of REGENERON PHARMACEUTICALS INC and the rest of the companies in the market in Cinco Días."
["url"]=>
string(93) "https://cincodias.elpais.com/mercados/empresas/regeneron_pharmaceuticals_inc/56805/historico/"
["image_url"]=>
NULL
["source"]=>
string(10) "elpais.com"
["publication_date"]=>
string(10) "2023-04-04"
["categories"]=>
array(1) {
[0]=>
string(21) "Competitive Behaviour"
}
}
[7]=>
array(7) {
["title_en"]=>
string(57) "Amgen-Sanofi patent case divides makers of antibody drugs"
["snippet_en"]=>
string(241) "Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines."
["url"]=>
string(96) "https://www.reuters.com/legal/amgen-sanofi-patent-case-divides-makers-antibody-drugs-2023-03-27/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/087ce6a6-f4b2-4e8e-bbb1-bda5831b72f8"
["source"]=>
string(11) "reuters.com"
["publication_date"]=>
string(10) "2023-03-27"
["categories"]=>
array(10) {
[0]=>
string(46) "Management of Legal and Regulatory Environment"
[1]=>
string(5) "Legal"
[2]=>
string(10) "Litigation"
[3]=>
string(21) "Intellectual Property"
[4]=>
string(8) "Verdicts"
[5]=>
string(11) "Regulations"
[6]=>
string(11) "Competition"
[7]=>
string(21) "Competitive Behaviour"
[8]=>
string(11) "Legislation"
[9]=>
string(15) "Business Ethics"
}
}
[8]=>
array(7) {
["title_en"]=>
string(42) "Regeneron Stock Increases Over 6%: Details"
["snippet_en"]=>
string(113) "The stock price of Regeneron Pharmaceuticals Inc (NASDAQ: REGN) increased by over 6% intraday today. This is why."
["url"]=>
string(60) "https://pulse2.com/regeneron-stock-increases-over-6-details/"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/bf94010c-1fac-4788-8b2e-9eb8add295dd"
["source"]=>
string(10) "pulse2.com"
["publication_date"]=>
string(10) "2023-03-23"
["categories"]=>
array(3) {
[0]=>
string(21) "Competitive Behaviour"
[1]=>
string(24) "Stock Research & Ratings"
[2]=>
string(12) "Stock Market"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(197)
}
[1]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(193)
}
[2]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(152)
}
[3]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(100)
}
[4]=>
array(2) {
["name"]=>
string(5) "Award"
["count"]=>
int(95)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(83)
}
[6]=>
array(2) {
["name"]=>
string(5) "Event"
["count"]=>
int(70)
}
[7]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(61)
}
[8]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(51)
}
[9]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(50)
}
[10]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(46)
}
[11]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(44)
}
[12]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(35)
}
[13]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(35)
}
[14]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(34)
}
[15]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(33)
}
[16]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(33)
}
[17]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(32)
}
[18]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(31)
}
[19]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(31)
}
[20]=>
array(2) {
["name"]=>
string(14) "Product Review"
["count"]=>
int(31)
}
[21]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(29)
}
[22]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(29)
}
[23]=>
array(2) {
["name"]=>
string(8) "Verdicts"
["count"]=>
int(29)
}
[24]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(27)
}
[25]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(26)
}
[26]=>
array(2) {
["name"]=>
string(13) "Data Security"
["count"]=>
int(24)
}
[27]=>
array(2) {
["name"]=>
string(24) "Access and affordability"
["count"]=>
int(23)
}
[28]=>
array(2) {
["name"]=>
string(11) "Sponsorship"
["count"]=>
int(20)
}
[29]=>
array(2) {
["name"]=>
string(8) "Politics"
["count"]=>
int(20)
}
}
}
c469a-us-regeneron-pharmaceuticals-inc
Regeneron Pharmaceuticals Inc
Location
New York
Founded
1988-02-08
Website
https://www.regeneron.com
Articles
2437 Articles
Category
Pharmaceutical Preparations
Description
At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in.
Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media.
An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media.
Nomura downgraded Uber (NYSE:UBER) shares to neutral buy, raising their target price to $62 from $59, DKNews.kz reports. The firm believes the company's shares are now
Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
